Skip to main content

Emergent Biosolutions shares plunge by more than 37% after U.S. cancels deal with Covid vaccine maker

The company will forgo $180 million due to the contract's termination, executives told investors on a call.
Data & News supplied by
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.